采用清肺排毒汤联合西药43例与单用西药46例的新型冠状病毒肺炎临床疗效比较

doi:10.6040/j.issn.1671-7554.0.2020.0870

摘要/Abstract

摘要： 目的回顾性评价清肺排毒汤加减治疗新型冠状病毒肺炎(COVID-19)的临床疗效,探讨可能的机制。方法选取 2020 年 2月 10 日至 4 月 1 日在武汉大学人民医院东院感染病区收治的符合 COVID-19 确诊标准的出院病历资料89例,根据是否使用清肺排毒汤加减,分为基础组46例和联合组43例,基础组根据国家卫生健康委员会制定的《新型冠状病毒肺炎诊疗方案(试行第六版)》中推荐的西医治疗方案,联合组在西医治疗方案基础上加用清肺排毒汤加减,比较两组治疗前后血常规、C反应蛋白(CRP)、白介素-6(IL-6)、细胞免疫、生化系列、凝血系列等表达变化,观察两组患者胸部CT变化情况、核酸转阴时间和住院天数。符合正态分布的数值型资料采用配对或非配对的t检验进行组间比较;计数资料采用相对数描述,组间差异采用卡方检验。结果 (1)基础组和联合组患者治疗后中性粒细胞比例(NEU%)、CRP、IL-6、肌酸激酶(CK)、乳酸脱氢酶(LDH)、纤维蛋白原(Fib)、纤维蛋白原降解产物(FDP)表达水平均下降,差异有统计学意义(P均<0.05);治疗后的淋巴细胞比例(LYM%)、CD3、CD4、CD8细胞计数明显升高,差异有统计学意义(P均<0.05);联合组患者血清肌酐(SCr)及D-二聚体(DD)均降低,预估肾小球滤过率(eGFR)升高,差异有统计学意义(P均<0.05)。(2)与基础组相比,联合组CD3和IL-6治疗前后差值的差异有统计学意义(P均<0.05)。两组患者胸部CT改善程度无差异;与基础组相比,联合组患者住院天数明显缩短(P<0.01),核酸转阴时间缩短,但差异无统计学意义。结论 (1)基础组和联合组都可以降低COVID-19患者炎症水平,增强细胞免疫,改善肾脏功能,减轻高凝状态。(2)与基础组相比,联合治疗可显著降低COVID-19患者IL-6的表达,升高细胞免疫中CD3水平,中西医结合治疗可显著抑制炎症反应,增强机体免疫力,缩短患者住院天数和核酸转阴时间,取得更好的临床疗效。

关键词: 清肺排毒汤加减, 新型冠状病毒肺炎, 临床研究, 炎症因子, 细胞免疫

Abstract: Objective To retrospectively evaluate the clinical efficacy of Qingfei Paidu decoction in the treatment of coronavirus disease 2019(COVID-19)and to explore the possible mechanism. Methods A total of 89 COVID-19 patiests whose date of discharge ranged from Feb. 10 to Apr. 1, 2020 were selected in the infection ward of the East Hospital of Renmin Hospital of Wuhan University. According to whether Qingfei Paidu decoction was used, 89 cases were divided into basic treatment group(n=46)and combined treatment group(n=43). The paitents in basic treatment group were only given western medicine treatment, while those in combined treatment group were treated with modified Qingfei Paidu decoction on the basis of western medicine treatment plan. The changes of blood routine, C reactive protein(CRP), interleukin-6(IL-6), cellular immunity, biochemical series and coagulation series were compared between the two groups before and after treatment. The changes of lung CT, the time of nucleic acid turning negative, and the patients hospitalization time were collected. A pairwise or non-paired t test was used to compare numerical data with normal distribution; the counting data were described by relative numbers, and the differences between groups were tested by chi-square test. Results (1) After the treatment, the expression levels of neutrophil ratio(NEU%), CRP, IL-6, creatine kinase(CK), lactate dehydrogenase(LDH), fibrinogen(Fib)and fibrinogen degradation product(FDP)were decreased in the two groups(P<0.05); the counts of lymphocyte ratio(LYM%), CD3, CD4 and CD8 T cells were significantly increased in the two groups(P<0.05); the levels of serum creatinine(SCr)and D-dimer(DD)were decreased while the estimated glomerular filtration rate(eGFR)was increased in the combined treatment group(P<0.05). (2) Compared with the basic treatment group, the difference of CD3 and IL-6 before and after treatment in the combination treatment group was statistically significant(P<0.05). There was no difference in the degree of improvement of chest CT between the two groups. The length of hospital stay in the combined treatment group was shorter than that in the basic treatment group(P<0.01), and the nucleic acid conversion time was shorter without statistical difference. Conclusion (1) The level of inflammation is reduced, cellular immunity is enhanced, renal function is improved, and hypercoagulability is reduced in both the basic treatment group and combined treatment group. (2) Compared with the basic treatment group, modified Qingfei Paidu decoction can significantly reduce the level of IL-6 and increase the level of CD3 of COVID-19 patients. The treatment of integrated traditional Chinese medicine and western medicine can significantly inhibit the inflammatory reaction, enhance the bodys immunity, and shorten the length of hospitalization and nucleic acid negative time, which help to get a better clinical efficacy.

Key words: Modified Qingfei Paidu decoction, Coronavirus disease 2019, Clinical study, Inflammatory factors, Cell-mediated immunity

中图分类号:

R243

余雪源,张硕,燕芳芳,苏德振. 采用清肺排毒汤联合西药43例与单用西药46例的新型冠状病毒肺炎临床疗效比较[J]. 山东大学学报 (医学版), 2020, 58(12): 47-53.

YU Xueyuan, ZHANG Shuo, YAN Fangfang, SU Dezhen. Comparison of clinical efficacy of Qingfei Paidu decoction combined with western medicine in 43 cases and single western medicine in 46 cases in the treatment of COVID-19[J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 47-53.

参考文献

[1] World Health Organization. WHO Director-generals remarks at the media briefing on 2019-nCoV on 11 February 2020 [EB/OL].(2020-2-12)[2020-05-27]. https://www.who.int/dg/speeches/detail/who director generals remarks at the media briefing on 2019 nCoV on February 2020.
[2] Wang W, Tang J, Wei F, et al. Updated understanding of the outbreak of 2019 novel corona virus(2019-nCoV)in Wuhan, China[J]. J Med Virol, 2020, 92(4): 441-447.
[3] 贾振华, 李红蓉, 常丽萍, 等. 中医学应对疫病的历史回顾与思考 [J]. 中国实验方剂学杂志, 2020, 26(11): 1-7. JIA Zhenhua, LI Hongrong, CHANG Liping, et al. Historical review and reflection about application of traditional Chinese medicine in epidemic diseases[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020, 26(11): 1-7.
[4] 国家卫生健康委办公厅. 国家卫生健康委办公厅关于印发新型冠状病毒感染的肺炎防控方案(第三版)的通知 [EB/OL].(2020-01-28)[2020-05-27]. http://www.gov.cn/zhengce/zhengceku/2020-01/29/content_5472893.htm.
[5] 国家卫生健康委办公厅, 国家中医药管理局办公室. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第七版)的通知 [EB/OL].(2020-03-03)[2020-05-27]. http://www.gov.cn/zhengce/zhengceku/2020-03/04/co-ntent_5486705.htm.
[6] 国家卫生健康委办公厅. 关于印发新型冠状病毒肺炎防控方案(第六版)的通知 [EB/OL].(2020-03-07)[2020-05-27]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml.
[7] 黄明, 杨丰文, 张磊, 等. 中医药治疗新型冠状病毒肺炎的经验与策略——张伯礼院士武汉一线抗疫思考[J/OL]. 中医杂志,2020. https://kns.cnki.net/kcms/detail/11.2166.R.20200927.0943002.html.
[8] 刘茜,王荣帅,屈国强,等. 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 法医学杂志, 2020, 36(1): 21-23.
[9] 袁红瑛,王勇,张继学,等. 成人病毒性肺炎患者肺泡灌洗液中T细胞亚群检测的临床意义[J].中国现代医学杂志, 2015, 25(7): 41-43. YUAN Hongying, WANG Yong, ZHANG Jixue, et al. Clinical significance of T cell subsets detection of bronchoalveolar lavage fluid in adult patients with virus pneumonia[J]. China Journal of Modern Medicine, 2015, 25(7): 41-43.
[10] Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a Meta-analysis[J]. Cytometry A, 2020, 97(8): 772-776.
[11] Xu B, Fan CY, Wang AL, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China[J]. J Infect, 2020,81(1):e51-e60. doi: 10.1016/j.jinf.2020.04.012.
[12] 胡家光,蒋忠胜,李旭,等. 新型冠状病毒肺炎患者16例外周血T淋巴细胞亚群的变化及意义[J].广东医学, 2020, 41(8): 781-783. HU Jiaguang, JIANG Zhongsheng, LI Xu, et al. The changes and clinical significance of peripheral T lymphocyte subsets in 16 patients with coronavirus disease 2019[J]. Guangdong Medical Journal, 2020, 41(8): 781-783.
[13] 李丹, 王梦龙, 何兵,等. 62 例新型冠状病毒肺炎患者的实验室指标分析[J]. 武汉大学学报(医学版), 2020, 41(6): 861-865. LI Dan, WANG Menglong, HE Bing, et al. Laboratory test analysis of sixty-two COVID-19 patients[J]. Medical Journal of Wuhan University, 2020, 41(6): 861-865.
[14] Liu F, Li L, Xu MD, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 [J]. J Clin Virol, 2020, 127:104370. doi: 10.1016/j.jcv.2020.104370.
[15] Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[16] Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia(NCP)[EB/OL]. MedRxiv, 2020. https://doi.org/10.1101/2020.02.10.20021832.
[17] 吕永,乐悦,王汉兵,等.新型冠状病毒肺炎脏器损伤及治疗策略研究进展[J].广东医学, 2020, 41(15): 1513-1517.
[18] 刘川,江自成,邵初晓,等.新型冠状病毒肺炎与肝功能损伤的关系初探:一项多中心研究[J].中华肝脏病杂志, 2020, 28(1): 148-152.
[19] Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan City, China [J]. Liver Int, 2020,40(9):2095-2103.
[20] 陈星,区静怡,黄颖,等.多种血液学指标在新型冠状病毒肺炎中的诊断价值[J].检验医学, 2020, 35(4): 295-299. CHEN Xing, OU Jingyi, HUANG Ying, et al. Diagnostic roles of several parameters in corona virus disease 2019[J]. Laboratory Medicine, 2020, 35(4): 295-299.
[21] Cheng YC, Luo R, Wang K, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients[J]. Kidney Int, 2020, 97(5): 829-838.
[22] Tang N, Li DJ, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(4): 844-847.
[23] Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection[J]. Clin Chem Lab Med, 2020, 58(7): 1116-1120.
[24] Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19[J]. J Thromb Haemost, 2020, 18(6):1324-1329.
[25] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11): 1061-1069.

相关文章 15

[1]	索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1-6.
[2]	杨张杰,王宇欣,陈冬梅,赵帅,虎娜,马良宏,马会明. 枸杞籽油对小鼠睾丸支持细胞衰老模型的抗炎作用[J]. 山东大学学报 (医学版), 2020, 58(12): 15-22.
[3]	牛占丛,王彦霞,王晓亚,王晓庆,李亚轻,边竞. 新型冠状病毒肺炎2例报告[J]. 山东大学学报 (医学版), 2020, 58(10): 134-136.
[4]	李秀君,李新楼,刘昆,赵晓波,马盟,孙博. 地理信息系统在新型冠状病毒肺炎疫情防控中的应用进展述评[J]. 山东大学学报 (医学版), 2020, 58(10): 13-19.
[5]	徐丽君,刘文辉,刘远,李美霞,罗雷,欧春泉. SEIQCR传染病模型的构建及在广州市新型冠状病毒肺炎公共卫生防控效果评估中的应用[J]. 山东大学学报 (医学版), 2020, 58(10): 20-24.
[6]	金新叶,卢珍珍,丁中兴,陈峰,彭志行. 武汉交通管制和集中隔离对新型冠状病毒肺炎疫情影响的动力学模型研究[J]. 山东大学学报 (医学版), 2020, 58(10): 25-31.
[7]	朱雨辰,李春雨,齐畅,王莹,刘利利,张丹丹,王旭,康殿民,李秀君. 基于泊松过程的山东省新型冠状病毒肺炎的再生数估计及流行动态分析[J]. 山东大学学报 (医学版), 2020, 58(10): 32-37.
[8]	李春雨,朱雨辰,齐畅,刘利利,张丹丹,王旭,徐学利,李秀君. 河南省信阳市新型冠状病毒肺炎的流行动态[J]. 山东大学学报 (医学版), 2020, 58(10): 38-43.
[9]	佘凯丽,张丹丹,齐畅,刘廷轩,贾艳,朱雨辰,李春雨,刘利利,王旭,苏虹,李秀君. 安徽省新型冠状病毒肺炎流行病学特征及其潜伏期估计[J]. 山东大学学报 (医学版), 2020, 58(10): 44-52.
[10]	齐畅,朱雨辰,李春雨,刘利利,张丹丹,王旭,佘凯丽,陈鸣,康殿民,李秀君. 基于地理加权广义线性模型探索山东省新型冠状病毒肺炎的影响因素[J]. 山东大学学报 (医学版), 2020, 58(10): 53-59.
[11]	贾艳,李春雨,刘利利,佘凯丽,刘廷轩,朱雨辰,齐畅,张丹丹,王旭,陈恩富,李秀君. 浙江省新型冠状病毒肺炎的流行特征与空间分析[J]. 山东大学学报 (医学版), 2020, 58(10): 66-73.
[12]	刘廷轩,齐畅,佘凯丽,贾艳,朱雨辰,李春雨,刘利利,王旭,章志华,李秀君. 河北省新型冠状病毒肺炎流行特征与时空聚集性分析[J]. 山东大学学报 (医学版), 2020, 58(10): 74-81.
[13]	刘利利,贾艳,齐畅,朱雨辰,李春雨,佘凯丽,刘廷轩,李秀君. 基于时空统计方法分析温州市2020年1~3月新型冠状病毒肺炎的聚集性分布[J]. 山东大学学报 (医学版), 2020, 58(10): 82-88.
[14]	张辉, 宋姝璇, 刘继锋, 贺真, 邵中军, 刘昆. 西安市新型冠状病毒肺炎疫情分析[J]. 山东大学学报 (医学版), 2020, 58(10): 89-94.
[15]	白尧,陈志军,宋姝璇,贺真,陈保忠,邵中军,刘昆. 西安市一起新型冠状病毒肺炎家族聚集性疫情调查分析[J]. 山东大学学报 (医学版), 2020, 58(10): 95-99.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed